Molecular pharmacology of the mineralocorticoid receptor: Prospects for novel therapeutics

@article{Kolkhof2012MolecularPO,
  title={Molecular pharmacology of the mineralocorticoid receptor: Prospects for novel therapeutics},
  author={Peter Kolkhof and Steffen A Borden},
  journal={Molecular and Cellular Endocrinology},
  year={2012},
  volume={350},
  pages={310-317}
}
The blockade of mineralocorticoid receptors (MR) has been shown to be an invaluable therapy in heart failure and hypertension. To date, only two steroidal antimineralocorticoids, spironolactone (and its active metabolite canrenone) and eplerenone, have been approved, whereas novel non-steroidal compounds are in preclinical and early development. The careful investigation of the efficacy and tolerance of spironolactone in essential hypertension initially supported the idea that a more selective… Expand
Emerging Roles of the Mineralocorticoid Receptor in Pathology: Toward New Paradigms in Clinical Pharmacology
TLDR
Excess mineralocorticoid signaling now appears deleterious in the progression of pathologies that may lead to end-stage organ failure and could therefore benefit from the repositioning of pharmacological MR antagonists. Expand
Safety profile of mineralocorticoid receptor antagonists: Spironolactone and eplerenone.
TLDR
Treatment with eplerenone has been associated with decreased blood pressure and improved survival for patients with heart failure and reduced left ventricular ejection fraction, and severe adverse effects such as gynecomastia and vaginal bleeding seem to be less likely in patients who take epleRenone than in those who take spironolactone. Expand
Third-generation Mineralocorticoid Receptor Antagonists: Why Do We Need a Fourth?
TLDR
Efforts to develop a third-generation MR antagonist are described and why fourth generation antagonists and selective agonists based on structural determinants of tissue and ligand-specific MR activation should be contemplated are contemplated. Expand
Discovery of BAY 94‐8862: A Nonsteroidal Antagonist of the Mineralocorticoid Receptor for the Treatment of Cardiorenal Diseases
TLDR
An extended SAR exploration starting from cyano‐1,4‐dihydropyridines that were identified by high‐throughput screening led to the identification of a dihydronaphthyridine, BAY 94‐8862, which is a potent, selective, and orally available nonsteroidal MR antagonist currently under investigation in a clinical phase II trial. Expand
Nonsteroidal antagonists of the mineralocorticoid receptor
TLDR
This review analyses the evidence for the potential of improved safety profiles of nonsteroid MRAs and the current landscape of clinical trials with nonsteroidal MRAs to overcome the limitations of today's steroidal antagonists. Expand
Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine
TLDR
Overall, nonsteroidal MRAs appear to demonstrate a better benefit–risk ratio than steroidal MRAs, where risk is measured as the propensity for hyperkalaemia. Expand
Mineralocorticoid receptor antagonists-pharmacodynamics and pharmacokinetic differences.
TLDR
A number of novel non-steroidal compounds are in preclinical and early development, with one agent moving to phase III trials and the development of these agents and the mechanisms for their pharmacologic superiority compared to earlier generations of MRAs will be discussed. Expand
Targeting the mineralocorticoid receptor in cardiovascular disease
  • M. Young
  • Biology, Medicine
  • Expert opinion on therapeutic targets
  • 2013
TLDR
The function of the MR is addressed, and its regulation of the cellular mechanisms that determine cell-specific MR signaling in cardiovascular disease are addressed and the potential for novel therapeutic targets that will allow for cardiac selective MR blockade is discussed. Expand
Interfering with mineralocorticoid receptor activation: the past, present, and future
TLDR
Advances have been made that could potentially increase the clinical use of agents that inhibit the actions of aldosterone, and these will be discussed here along with some examples of the beneficial effects of these new therapeutic agents. Expand
Nonsteroidal Mineralocorticoid Receptor Antagonists: Exploring Role in Cardiovascular Disease.
TLDR
It seems that there could be a future role for nonsteroidal MRAs to reduce the risk of renal outcomes in high-risk individuals. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 85 REFERENCES
Reconsidering the Roles of the Mineralocorticoid Receptor
TLDR
The present review focuses on the clinical study (Randomized ALdactone Evaluation Study [RALES]], in patients with New York Heart Association class III heart failure, that prompted this process of re-examination almost a decade ago. Expand
Pharmacokinetics and Pharmacodynamics of Mineralocorticoid Blocking Agents and their Effects on Potassium Homeostasis
  • D. Sica
  • Medicine
  • Heart Failure Reviews
  • 2005
TLDR
Both eplerenone and spironolactone are effective antihypertensive agents and each has been shown to improve the morbidity and mortality of heart failure and use can increase serum potassium values and occasionally results in clinically relevant hyperkalemia. Expand
Molecular mechanisms of mineralocorticoid receptor antagonism by eplerenone.
TLDR
The preclinical and clinical evidence supporting the beneficial effects of eplerenone (INSPRA), a selective aldosterone blocker, in the treatment of hypertension and heart failure is summarized and the current status in understanding the molecular mechanisms of action of the MR and its ligand is reviewed. Expand
A New Mode of Mineralocorticoid Receptor Antagonism by a Potent and Selective Nonsteroidal Molecule*
TLDR
It is proposed that BR-4628 is a bulky antagonist that inactivates MR through a passive mechanism and represents the prototype of a new class of MR antagonists. Expand
Non-steroidal mineralocorticoid receptor antagonists
TLDR
This review summarizes the existing information available on non-steroidal MR antagonists from patent applications and the scientific literature published since 2003 to be beneficial to patients with high blood pressure and other cardiovascular diseases, such as heart failure. Expand
Antiandrogenic effect of spirolactones: mechanism of action.
TLDR
It seems likely that spirolactones, besides their action on testosterone biosynthesis, exert their antiandrogenic activity via a peripheral androgen antagonism. Expand
The 45-year story of the development of an anti-aldosterone more specific than spironolactone
  • J. Ménard
  • Medicine
  • Molecular and Cellular Endocrinology
  • 2004
TLDR
The absence of sexual side-effects has confirmed the clinical relevance of the initial biological hypothesis on the need for more selectivity at the androgen and progestogen receptor sites and Widening the distance between efficacy and adverse effects of an anti-mineralocorticoid drug will facilitate the long-term maintenance of a moderately negative sodium balance and a slightly positive potassium balance. Expand
Aldosterone antagonists destabilize the mineralocorticosteroid receptor.
TLDR
It is proposed that the combination of rapid dissociation of the ligand and a weakened hsp90-receptor interaction is involved in the anti-mineralococorticosteroid activity of aldosterone antagonists. Expand
Discovery of novel cyanodihydropyridines as potent mineralocorticoid receptor antagonists.
TLDR
The structure-activity relationships of this novel series of cyano ester dihydropyridines resulted in R6 substituted analogues with improved metabolic stability while maintaining excellent MR antagonist activity and selectivity against other nuclear receptors. Expand
The mineralocorticoid receptor: a journey exploring its diversity and specificity of action.
TLDR
The multiple levels of MR selectivity over other steroid receptors, in particular GR, will be described as well as the consequences for aldosterone-regulated gene expression. Expand
...
1
2
3
4
5
...